Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

NCT02639910 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: Tafasitamab
DRUG: Idelalisib
DRUG: Venetoclax

Sponsor

MorphoSys AG